Company Research Report: Healx Ltd.

---

Company Overview

• Name: Healx Ltd.

• Mission: Healx is dedicated to transforming lives for rare disease patients by leveraging AI and other advanced technologies to discover and develop treatments more effectively and efficiently.

• Founded: 2014

• Founders: Dr. Tim Guilliams and Dr. David Brown

• Key People:

• Dr. Tim Guilliams, Co-founder and CEO

• Dr. Bruce Bloom, Chief Collaboration Officer

• Dr. Mark Youssef, Global Head of Business Development and Licensing

• Trevor Bennington, Senior Finance Director

• Nick Street, Head of Operations, People & Tech

• Richard Davenport, Senior Director, Drug Discovery

• Miguel Pignatelli, Director, Tech Strategy

• Hanna Orr MFPM, Medical Director

• Simone Manso, Head of Neurofibromatosis Therapy Development

• Headquarters: Charter House, 66-68 Hills Rd, Cambridge, CB2 1LA, UK

• Number of Employees: No information is available

• Revenue: No information is available

• Noteworthy Achievements: Healx is renowned for its innovative approach to drug discovery using AI and frontier technologies to enhance the success rate of developing treatments for rare diseases.

Products

• Product Offerings: Healx is focused on the development of therapeutics for rare diseases.

• Product Descriptions: The company leverages its AI-driven platform, Healnet, to identify and repurpose existing drugs for treating rare diseases.

• Product Pipeline:

• HLX-1502: Targeting Neurofibromatosis Type 1 (NF1)

• Key Features: It has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, aiming to provide a novel, first-in-class therapeutic option for NF1.

Recent Developments

• New Product Development:

• HLX-1502: Receives Fast Track designation by the FDA for treatment of NF1. It is currently being advanced into Phase 2 clinical trials.

• Recent Financial Developments:

• Secured $47 million in a Series C financing round co-led by R42 Group and Atomico. The funds are allocated to support the development pipeline and advance clinical programs including HLX-1502.

• Innovative Technological Developments:

• Continued development of "Healnet", an AI-driven drug discovery engine updated with generative AI capabilities to optimize drug discovery.

• Partnerships:

• Collaborations with Children’s Tumor Foundation, which provides milestone-driven payments to support the developments in the NF programs.

Technological Impact

• AI and Drug Discovery: Healx combines AI technology, including generative AI for predictive modeling and phenomics, to discover and develop novel treatments for rare diseases, allowing for improved treatment success rates and faster delivery to patients.

Awards and Recognition

• Life Sciences AI Awards 2024

• Best Use of AI in Health and Medicine 2019

• AI Company of the Year 2019

• Tech4Good Awards: AI for Good winner

• Multiple other awards recognizing social impact and technological innovation in drug discovery.

Contact Information

• Telephone: 01223 901980

• Website: [www.healx.ai](https://www.healx.ai)

Financial Highlights

• Investment: Approximately $110 million raised to date, including the recent Series C round.

Conclusion

Healx Ltd. is at the forefront of using AI to revolutionize drug discovery specifically for the rare disease market. With a robust pipeline, strategic partnerships, and significant investment backing, Healx is poised to make significant advances in addressing unmet medical needs in rare diseases.